Predictive value of anti-Müllerian hormone on pregnancy outcomes in in-vitro fertilization/intracytoplasmic single sperm injection patients at different ages

Purpose: To investigate the predictive value of AMH level for pregnancy outcomes in different age groups of IVF/ICSI patients. Methods: The study was a cohort study that included 11,484 patients that had their first IVF/ICSI procedure between 2016 and 2019. All patients who met the inclusion and exclusion criteria were divided into 6 groups according to 5-year age intervals, namely, Group 1: 20–24 years (n = 725); Group 2: 25–29 years (n = 4019); Group 3: 30–34 years (n = 3600); Group 4: 35–39 years (n = 1915); Group 5: 40–44 years (n = 1006); and Group 6: ≥ 45 years (n = 219). Results: Receiver operating characteristic (ROC) curve analysis revealed that AMH level could only predict the outcome of live birth in Group 3 and Group 4 (p < 0.05). The area under the curve (AUC) of Group 3 was 0.536 (95% CI 0.510–0.561, p = 0.006), and that of Group 4 was 0.562 (95% CI 0.527–0.598, p = 0.001). The cutoff values of AMH for predicting live birth in Group 3 and Group 4 were 1.84 ng/ml and 1.86 ng/ml, respectively. Further logistic regression analysis showed that only the cutoff values of AMH and age could predict live birth in Groups 3 and 4. Conclusions: AMH level could predict live birth in IVF/ICSI patients at the age of 30–39. However, it could not be used to predict live birth in patients < 30 years or ≥ 40 years.